SAN DIEGO and TORONTO, April 24, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Bloom Burton & Co. Healthcare Conference on Wednesday, May 2, 2018 at 1:30 p.m. EDT:
| Time: | 1:30 p.m. EDT | |
| Date: | Wednesday, May 2, 2018 | |
| Location: | Sheraton Centre Toronto Hotel, Toronto, Canada | |
| Live webcast: | http://wsw.com/webcast/bloomburton3/apto |
The audio webcast can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Bloom Burton & Co.:
Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
| SMP Communications Susan Pietropaolo 201-923-2049 [email protected] | LifeSci Advisors Michael Wood Managing Director 646-597-6983 [email protected] |


Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Same sparkle, different story: how lab-grown diamonds are transforming the market
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Capital One Says AML Review Led to Closure of Trump Organization Accounts
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 



